Bible KC - Search Results

1

Combined lenvatinib and pembrolizumab as salvage therapy in advanced adrenal cortical carcinoma.

Bedrose S, Miller KC, Altameemi L, Ali MS, Nassar S, Garg N, Daher M, Eaton KD, Yorio JT, Daniel DB, Campbell M, Bible KC, Ryder M, Chintakuntlawar AV, Habra MA. Bedrose S, et al. Among authors: bible kc. J Immunother Cancer. 2020 Jul;8(2):e001009. doi: 10.1136/jitc-2020-001009. J Immunother Cancer. 2020. PMID: 32737143 Free PMC article.

2

Enhanced survival in locoregionally confined anaplastic thyroid carcinoma: a single-institution experience using aggressive multimodal therapy.

Foote RL, Molina JR, Kasperbauer JL, Lloyd RV, McIver B, Morris JC, Grant CS, Thompson GB, Richards ML, Hay ID, Smallridge RC, Bible KC. Foote RL, et al. Among authors: bible kc. Thyroid. 2011 Jan;21(1):25-30. doi: 10.1089/thy.2010.0220. Epub 2010 Dec 16. Thyroid. 2011. PMID: 21162687

3

Evolving molecularly targeted therapies for advanced-stage thyroid cancers.

Bible KC, Ryder M. Bible KC, et al. Nat Rev Clin Oncol. 2016 Jul;13(7):403-16. doi: 10.1038/nrclinonc.2016.19. Epub 2016 Mar 1. Nat Rev Clin Oncol. 2016. PMID: 26925962 Review.

4

Promises and Perils of Molecularly Targeted Therapeutics in Anaplastic Thyroid Cancer.

Bible KC, Chintakuntlawar AV, Ryder M. Bible KC, et al. J Oncol Pract. 2016 Jun;12(6):521-2. doi: 10.1200/JOP.2016.013144. J Oncol Pract. 2016. PMID: 27288466 No abstract available.

5

Mutated BRAF and personalised medicine in differentiated thyroid cancer.

Bible KC, Ryder M. Bible KC, et al. Lancet Oncol. 2016 Sep;17(9):1181-3. doi: 10.1016/S1470-2045(16)30230-3. Epub 2016 Jul 23. Lancet Oncol. 2016. PMID: 27460441 No abstract available.

6

Leveraging the immune system to treat advanced thyroid cancers.

French JD, Bible K, Spitzweg C, Haugen BR, Ryder M. French JD, et al. Lancet Diabetes Endocrinol. 2017 Jun;5(6):469-481. doi: 10.1016/S2213-8587(16)30277-7. Epub 2016 Oct 20. Lancet Diabetes Endocrinol. 2017. PMID: 27773653 Review.

7

Expression of PD-1 and PD-L1 in Anaplastic Thyroid Cancer Patients Treated With Multimodal Therapy: Results From a Retrospective Study.

Chintakuntlawar AV, Rumilla KM, Smith CY, Jenkins SM, Foote RL, Kasperbauer JL, Morris JC, Ryder M, Alsidawi S, Hilger C, Bible KC. Chintakuntlawar AV, et al. Among authors: bible kc. J Clin Endocrinol Metab. 2017 Jun 1;102(6):1943-1950. doi: 10.1210/jc.2016-3756. J Clin Endocrinol Metab. 2017. PMID: 28324060

8

Salvage Lenvatinib Therapy in Metastatic Anaplastic Thyroid Cancer.

Iñiguez-Ariza NM, Ryder MM, Hilger CR, Bible KC. Iñiguez-Ariza NM, et al. Among authors: bible kc. Thyroid. 2017 Jul;27(7):923-927. doi: 10.1089/thy.2016.0627. Epub 2017 May 31. Thyroid. 2017. PMID: 28471306

9

OPTIMIZING LENVATINIB THERAPY IN PATIENTS WITH METASTATIC RADIOACTIVE IODINE-RESISTANT DIFFERENTIATED THYROID CANCERS.

Jasim S, Iniguez-Ariza NM, Hilger CR, Chintakuntlawar AV, Ryder MM, Morris JC 3rd, Bible KC. Jasim S, et al. Among authors: bible kc. Endocr Pract. 2017 Oct;23(10):1254-1261. doi: 10.4158/EP171822.OR. Epub 2017 Aug 17. Endocr Pract. 2017. PMID: 28816536

10

Survival in Response to Multimodal Therapy in Anaplastic Thyroid Cancer.

Prasongsook N, Kumar A, Chintakuntlawar AV, Foote RL, Kasperbauer J, Molina J, Garces Y, Ma D, Wittich MAN, Rubin J, Richardson R, Morris J, Hay I, Fatourechi V, McIver B, Ryder M, Thompson G, Grant C, Richards M, Sebo TJ, Rivera M, Suman V, Jenkins SM, Smallridge RC, Bible KC. Prasongsook N, et al. Among authors: bible kc. J Clin Endocrinol Metab. 2017 Dec 1;102(12):4506-4514. doi: 10.1210/jc.2017-01180. J Clin Endocrinol Metab. 2017. PMID: 29029287

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

89 results

Search Page